They first proved that NF1 mutations act via the NF1–MAPK–FOSL1 axis in MES gliomas as they increase FOSL1 RNA and protein expression and therefore activate the expression of the MES gene signature and inhibit the non-MES gene signature [113]. Here, NF1 is linked to central nervous system cancer.